Top Industry News

Lonza has announced a new organization structure for its CDMO business and announced it plans to exit its Capsules & Health Ingredients business. The company made the announcement last month (December…

The latest from CDMOs, CMOs, and suppliers featuring NewBiologix and Scinai Bioservices.   Biologics Manufacturing * Cell & Gene Therapy Service Provider, NewBiologix, Launches US Subsidiary General * Scinai Bioservices Launches US Subsidiary  Biologics…

A roundup of news from AbbVie/Nimble Therapeutics and Juncell Therapeutics. Highlights below.   Mfg News * Juncell Therapeutics Opens New Mfg Facility in ChinaM&A News * AbbVie To Acquire Nimble Therapeutics for $200…

A roundup of bio/pharmaceutical partnering news from Merck & Co./Hansoh Pharma, Novo Nordisk/Photys Therapeutics, and Eli Lilly and Company/Innovent Biologics.  * Merck & Co., Hansoh Pharma in $2-Bn GLP-1 Small-Molecule…

Eli Lilly and Company has announced a $3-billion expansion of its sterile manufacturing facility in Pleasant Prairie, Wisconsin. Lilly had acquired the facility earlier this year (2024) from Nexus Pharmaceuticals,…

AbbVie has completed its $1.4-billion acquisition of Aliada Therapeutics, a bio/pharmaceutical company focused on central nervous system (CNS) diseases, for $1.4 billion. The companies had announced the acquisition in October…

The latest from CDMOs, CMOs, and suppliers featuring Euroapi & SK pharmteco.   Chemicals/Chemical API Manufacturing* Euroapi Names New Chair & CEO General * SK pharmteco Consolidates Brands into One Company Chemicals/Chemical API…

A roundup of bio/pharmaceutical partnering news from Gilead/Tubulis and Takeda/Keros.  * Gilead, Tubulis In $465-M ADC Cancer Drug Pact * Takeda, Keros Therapeutics in $200-M Cancer Drug Licensing Pact  Gilead, Tubulis…

Sanofi has signed a memorandum of cooperation with the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Economic and Technological Development Zone to establish a new EUR…

Amgen has announced a $1-billion expansion to establish a second drug substance manufacturing facility in Holly Springs, North Carolina. This brings the company’s total planned investment in Holly Springs to…